Analysis of Covid 19’s impact on Medical Aesthetics.
The fast forward evolution to digitalization and increased safety – M&A and Capital Markets Analysis. Last Years’ ever-increasing M&A momentum has been first severely hit by the COVID pandemic leading to a financial crunch and downward forecast revisions, 2020 budgets being discounted by 25 to 40% and 2021 projections by at least 10% with a full recovery only in 2022 . It nearly ground to a halt during the hard lock-down period but showed resilience after release of the lack-down and has resumed in H2. Despite poor results in 2020 compared to M&A activity in 2019, the year 2020 is expected to overperform 2018 – If we normalize the year 2020 considering only 9 months of M&A activity, the normalized total value would be €2,166m to date, already outpacing 2018. This follows a similar evolution as the severe reduction in Biopharma M&A deals in H1 2020 vs. 2019, which were also penalized by the COVID pandemic, sinking from $ 140bn to $ 14bn.
